Close
Smartlab Europe
Inizio Ignite

Ranbaxy launches cholesterol reducing drug in Australia

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Sustainable Chemical Processes in Drug Manufacturing

Implementing green chemistry principles and sustainable chemical engineering in drug production is essential for reducing environmental impact and improving resource efficiency.

Novartis Breaks Ground on San Diego Biomedical R&D Site

Novartis has started work on a $1.1 billion biomedical...

Excipients Innovation Transforming Drug Delivery Performance

Analysis of the evolving role of functional excipients in modern pharmacology, moving beyond inert fillers to become active participants in drug stability and targeted release.
- Advertisement -

Ranbaxy Australia, a subsidiary of Ranbaxy Laboratories, has introduced Atorvastatin 10mg, 20mg, 40mg and 80mg tablets after receiving approval from Therapeutic Goods Administration (TGA) in Australia.

The product is launched under the brand name Trovas in bottles and blister packs, through retail pharmacy chains. Atorvastatin, a cholesterol reducing drug, is the most prescribed statin in Australia and represents the largest patent expiry opportunity ever, in the Australian pharmaceutical market, the company said. Ranbaxy Australia managing director Alex Evans said Ranbaxy is privileged to be the first generic pany in Australia to introduce Atorvastatin under the brand name, Trovas.

Latest stories

Related stories

Sustainable Chemical Processes in Drug Manufacturing

Implementing green chemistry principles and sustainable chemical engineering in drug production is essential for reducing environmental impact and improving resource efficiency.

Novartis Breaks Ground on San Diego Biomedical R&D Site

Novartis has started work on a $1.1 billion biomedical...

Excipients Innovation Transforming Drug Delivery Performance

Analysis of the evolving role of functional excipients in modern pharmacology, moving beyond inert fillers to become active participants in drug stability and targeted release.

Drug Device Combination Products Driving Delivery Precision

Deep dive into the convergence of medical engineering and pharmaceutical science, focusing on how integrated delivery systems enhance dosing accuracy and patient outcomes.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »